eXoZymes (EXOZ) Q2 2026 earnings summary

Executive summary

• Pre-revenue biotechnology company focused on synthetic biology platforms for scalable, sustainable chemical production targeting pharmaceuticals, fuels, materials, and food additives.

• Operates as a single reportable segment, with all activities managed on a consolidated basis.

Financial highlights

• Net loss for six months ended June 30, 2026 was $5.25 million, a 24.5% increase year-over-year.

• Total operating costs rose 18.7% year-over-year to $5.34 million, driven by higher R&D expenses.

• Cash and cash equivalents increased to $5.65 million as of June 30, 2026, up from $3.04 million at year-end 2025, primarily due to June 2026 equity offerings.

• Working capital improved to $4.55 million as of June 30, 2026.

• Net cash used in operating activities was $3.16 million for the six months ended June 30, 2026.

Outlook and guidance

• Management concluded that existing working capital is insufficient to fund operations for twelve months from the reporting date, raising substantial doubt about the ability to continue as a going concern.

• Plans to pursue additional non-dilutive funding, grants, and potential further equity or debt offerings.